A Phase 3 interventional study of rhPSMA-7.3 (18F) Injection and Positron Emission Tomography scan in Prostate Cancer, sponsored by Blue Earth Diagnostics. Completed at 34 sites in 4 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-26.
Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing flotufolastat F 18 in Prostatic Neoplasms — 6 open to participants now, 7 under way, 2 of them phase 3. flotufolastat F 18 · Prostatic Neoplasms.
Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is one of 2 that started in 2020, is one of 4 in phase 3, and was the 2nd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Men only
University of Florida · Sites in United States
Ages 18–100 · Men only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18–90 · Men only
Hackensack Meridian Health · Sites in United States
Ages 18+ · Men only
Emory University · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 4 · Phase 4 1
First in 2019; this study’s year is marked. 2 started in 2020.
This study's enrollment of 356 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 70 across the 15 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Blue Earth Diagnostics, one of the names counted as Bracco. Under that name alone:
Blue Earth Diagnostics is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
13 studies in Prostatic Neoplasms by Bracco: 2 open now, 2 under way, none of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 13 studies in Prostatic Neoplasms by Bracco, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 8th registered.
Bracco’s Prostatic Neoplasms studies by the year they started, since 2009.
1 of the studies testing flotufolastat F 18 in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07285057Icahn School of Medicine at Mount SinaiDiagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing flotufolastat F 18 in Prostatic Neoplasms, from their registry updates:
Among Bracco’s 13 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer.
Main objective is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central blinded image evaluation [BIE]) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during radical prostatectomy (RP) and pelvic lymph node dissection (PLND). At least one positive pelvic LN on PET (N1) and one positive lymph node (LN) as determined by histopathology (pN1) on the same side of the pelvis (left or right) will be deemed a True Positive (TP) at the patient level.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan
Drug: rhPSMA-7.3 (18F) Injection · Diagnostic Test: Positron Emission Tomography scan
Radioligand for PET CT scanning
Also known as: No other interventions
imaging test with radioligand
Also known as: PET scan
Specificity
The primary objective of the study is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central BIE) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND.
Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
Sensitivity
The primary objective of the study is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central BIE) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND.
Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
Verified Detection Rate (VDR) for M1 Lesions - Percentage of Patients in Whom rhPSMA-7.3 (18F) Imaging Detected at Least One Verified M1 Metastasis, as Determined by Central BIE and Confirmed by SoT (Biopsy or Imaging) (Objective 1)
This was a key secondary endpoint in this study and included patients in the EEP with rhPSMA-7.3 (18F) imaging.
Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET. followed by treatment within 60 days post IMP administration
Percentage of Patients With Negative Conventional Imaging for M1 Disease in Whom rhPSMA-7.3 (18F) PET Detected at Least One Verified M1 Metastasis, as Determined by Central BIE (Objective 2)
Patients counted in this variable were a subset of those in Point 1 above, where both the numerator and denominator were only counting patients with negative conventional imaging (according to investigator assessment) for M1 disease.
Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
Patient-level PPV of rhPSMA-7.3 (18F) PET BIE for N1 and M1 Lesions Compared to Histopathology or Confirmatory Imaging (M1 Lesions Only) (Objective 3)
This analysis included patients with rhPSMA-7.3 (18F) imaging and either N1 or M1 lesions detected, where PPV=TP/(TP+FP).
Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
PPV of rhPSMA-7.3 (18F) PET for Detecting PLN Metastases Compared to Surgical Pathology on a Patient-level, in Which a FP Patient is Defined as Having at Least One FP Region (Right or Left Pelvis), Regardless of Any Coexisting TP Findings (Objective 4)
This analysis included patients in the EAP where rhPSMA-7.3 (18F) imaging detected PLN metastasis. Regions where rhPSMA7.3 (18F) imaging detected no LN metastasis were not included (by definition of PPV), hence only TP and FP regions were considered. TPs were all patients with a surgical pathology confirmed positive region and without a FP region. FP patients were those patients with any rhPSMA7.3 (18F) PETpositive region with negative or no surgical pathology.
Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
NPV of rhPSMA-7.3 (18F) PET for Detecting PLN Metastases Compared to Surgical Pathology on a Patient-level, in Which a FN Patient is Defined as Having at Least One FN Region (Right or Left Pelvis), Regardless of Any Coexisting TN Findings (Objective 5)
This analysis included patients in the EAP with rhPSMA-7.3 (18F) imaging where no LN metastases were detected and LN surgical pathology was available; where NPV=TN/(TN+FN).
Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
The Percentage of Patients Being Upstaged to N1 or M1 Disease. (Objective 6a)
TP \[confirmed by SoT\] central BIE PET finding and negative conventional imaging finding from the local reading
Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
The Percentage of Patients in Whom Planned RP Was Converted to EBRT. (Objective 6b)
Time frame: Conventional images within 60 days or at least 24 hours prior to rhPSMA-7.3 (18F) PET, followed by treatment within 60 days post IMP administration
Kappa Statistic for the Agreement Between and Within Blinded Independent Readers on the Interpretation of rhPSMA-7.3 (18F) Scans (Objective 7)
Pairwise agreement between any 2 of the 3 readers (Kappa statistic could not be calculated for 2 of the pairwise agreements), and within readers between the initial read and re-read (Kappa statistics could not be calculated for 2 of the within-reader agreements)
Time frame: PET/CT scans on Day 1
This study was from 02 Mar 20 (first patient, screening visit) and 18 Feb 22 (database lock), with the last patient, last visit on 21 Jun 21. It was conducted at 34 activated study sites (31 recruited) in 4 countries. Of the 372 patients screened, 356 patients met all the study eligibility criteria. 16 patients were screen failures so not included
| Milestone | Patients |
|---|---|
| Started | 356 |
| Completed | 336 |
| Not completed | 20 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Opted for ebrt | 1 |
| Withdrew: Opted sbrt | 1 |
| Withdrew: Patient decided to have focal ablation and not surgery | 2 |
| Withdrew: Physician decision | 1 |
| Withdrew: Rp delayed | 1 |
| Withdrew: Sponsor decision: outdated fu timeline | 1 |
| Withdrew: Subject declined for financial reasons | 1 |
| Withdrew: The subject declined any biopsy or surgery due to covid-19 pandemic | 1 |
| Withdrew: The subject declined for any biopsy or other imaging | 2 |
| Withdrew: The subject opted for other treatment option | 2 |
| Withdrew: The subject opted for other treatment options | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Reason not specified | 1 |
The primary objective of the study is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central BIE) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND.
| percentage | Efficacy Analysis Population |
|---|---|
| Central Reader 1 | 92.9 (88.8 to 95.9) |
| Central Reader 2 | 93.8 (89.8 to 96.6) |
| Central Reader 3 | 96.9 (93.7 to 98.7) |
The primary objective of the study is to assess the sensitivity and specificity of rhPSMA-7.3 (18F) positron emission tomography (PET) in detecting N1 disease (as determined by the central BIE) on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND.
| percentage | Efficacy Analysis Population |
|---|---|
| Central Reader 1 | 30 (19.6 to 42.1) |
| Central Reader 2 | 27.1 (17.2 to 39.1) |
| Central Reader 3 | 22.9 (13.7 to 34.4) |
This was a key secondary endpoint in this study and included patients in the EEP with rhPSMA-7.3 (18F) imaging.
| percentage | Extended Efficacy Population (EEP) |
|---|---|
| Central Reader 1 | 9.9 (7.0 to 13.6) |
| Central Reader 2 | 14.2 (10.7 to 18.3) |
| Central Reader 3 | 10.2 (7.3 to 13.9) |
Patients counted in this variable were a subset of those in Point 1 above, where both the numerator and denominator were only counting patients with negative conventional imaging (according to investigator assessment) for M1 disease.
| percentage | Extended Efficacy Population (EEP) |
|---|---|
| Central Reader 1 | 8.8 (5.9 to 12.3) |
| Central Reader 2 | 13.0 (9.6 to 17.1) |
| Central Reader 3 | 8.5 (5.7 to 12.0) |
This analysis included patients with rhPSMA-7.3 (18F) imaging and either N1 or M1 lesions detected, where PPV=TP/(TP+FP).
| percentage | Efficacy Analysis Population (EAP) | Extended Efficacy Population (EEP) |
|---|---|---|
| Central Reader 1 | 56.8 (39.5 to 72.9) | 62.5 (48.5 to 75.1) |
| Central Reader 2 | 57.6 (39.2 to 74.5) | 51.0 (40.7 to 61.3) |
| Central Reader 3 | 69.6 (47.1 to 86.8) | 57.1 (44.0 to 69.5) |
This analysis included patients in the EAP where rhPSMA-7.3 (18F) imaging detected PLN metastasis. Regions where rhPSMA7.3 (18F) imaging detected no LN metastasis were not included (by definition of PPV), hence only TP and FP regions were considered. TPs were all patients with a surgical pathology confirmed positive region and without a FP region. FP patients were those patients with any rhPSMA7.3 (18F) PETpositive region with negative or no surgical pathology.
| percentage | Efficacy Analysis Population (EAP) |
|---|---|
| Central Reader 1 | 48.6 (31.9 to 65.6) |
| Central Reader 2 | 54.5 (36.4 to 71.9) |
| Central Reader 3 | 65.2 (42.7 to 83.6) |
This analysis included patients in the EAP with rhPSMA-7.3 (18F) imaging where no LN metastases were detected and LN surgical pathology was available; where NPV=TN/(TN+FN).
| percentage | Efficacy Analysis Population (EAP) |
|---|---|
| Central Reader 1 | 81.3 (76.3 to 85.7) |
| Central Reader 2 | 80.8 (75.8 to 85.2) |
| Central Reader 3 | 79.9 (74.8 to 84.4) |
TP \[confirmed by SoT\] central BIE PET finding and negative conventional imaging finding from the local reading
| percentage | Upstaged to N1 | Upstaged to M1 |
|---|---|---|
| Central Reader 1 | 5.1 | 8.2 |
| Central Reader 2 | 4.3 | 12.2 |
| Central Reader 3 | 3.7 | 8.0 |
| percentage | Extended Efficacy Population (EEP) |
|---|---|
| The Percentage of Patients in Whom Planned RP Was Converted to EBRT. (Objective 6b) | 2.6 |
Pairwise agreement between any 2 of the 3 readers (Kappa statistic could not be calculated for 2 of the pairwise agreements), and within readers between the initial read and re-read (Kappa statistics could not be calculated for 2 of the within-reader agreements)
| percentage | Extended Efficacy Population (EEP) |
|---|---|
| Agreement between reader 1 and reader 2 | 97.7 |
| Agreement between Reader 1 and Reader 3 | 95.2 |
| Agreement between Reader 2 and Reader 3 | 96.9 |
| Agreement between initial read and re-read in Reader 1 | 100 |
| Agreement between initial read and re-read in Reader 2 | 100 |
| Agreement between initial read and re-read in Reader 3 | 95.7 |
Collected over All AEs were recorded throughout the study from informed consent through study completion, an average of 60 days post-IMP administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Full Safety Population (FSP) | 0/356 (0%) | 0/356 (0%) | 28/356 (7.9%) |
| Event | Full Safety Population (FSP) |
|---|---|
| HeadacheNervous system disorders | 5/356 |
| Injection site painGeneral disorders | 3/356 |
| NauseaGastrointestinal disorders | 3/356 |
| HypertensionVascular disorders | 2/356 |
| Tracheal deviationInjury, poisoning and procedural complications | 1/356 |
| Aortic aneurysmVascular disorders | 1/356 |
| ThrombophlebitisVascular disorders | 1/356 |
| Atrial fibrillationCardiac disorders | 1/356 |
| DysgeusiaNervous system disorders | 1/356 |
| ChillsGeneral disorders | 1/356 |
The FAS comprised 356 patients who were scheduled to receive the rhPSMA-7.3 (18F) injection and met the inclusion/exclusion criteria
| Age, Continuous(years) | Single Arm |
|---|---|
| Mean | 64.9 ± 6.98 |
| Age, Customized(participants) | Single Arm |
|---|---|
| < 65 years | 163 |
| ≥ 65 years | 193 |
| Sex: Female, Male(Participants) | Single Arm |
|---|---|
| Female | 0 |
| Male | 356 |
| Ethnicity (NIH/OMB)(Participants) | Single Arm |
|---|---|
| Hispanic or Latino | 17 |
| Not Hispanic or Latino | 311 |
| Unknown or Not Reported | 28 |
| Race/Ethnicity, Customized(participants) | Single Arm |
|---|---|
| Black or African American | 30 |
| White | 289 |
| Other | 4 |
| Not Reported | 33 |
| Region of Enrollment(participants) | Single Arm |
|---|---|
| Netherlands | 14 |
| United States | 238 |
| Finland | 18 |
| Germany | 86 |
| Total Gleason Score(participants) | Single Arm |
|---|---|
| =7 | 160 |
| =8 | 87 |
| =9 | 97 |
| =10 | 6 |
| ≤ 6 | 6 |
| TNM (Tumor-Node-Metastasis) Stage T(participants) | Single Arm |
|---|---|
| T1 | 16 |
| T1a | 2 |
| T1c | 127 |
| T2 | 58 |
| T2a | 18 |
| T2b | 25 |
| T2c | 33 |
| T3 | 20 |
| T3a | 21 |
| T3b | 12 |
| T3c | 1 |
| T4 | 2 |
| TX | 9 |
| Missing | 12 |
9 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2020 to primary completion in Jun 2021, 15 months.
Results were first posted in Feb 2025, 3 years 8 months after primary completion. A results delay was requested in Mar 2022.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 15 months is below that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flotufolastat F 18